A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

NCT05656040 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

End-Stage Renal Disease
End-Stage Kidney Disease
Kidney Failure, Chronic

Interventions

BIOLOGICAL: MK-2060
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC